Axsome Therapeutics, Inc. (AXSM)

70,97 -0,55 (-0,77%) In data: 11:14AM EDT. Mercato aperto.

Axsome Therapeutics, Inc.

One World Trade Center
22nd Floor
New York, NY 10007
United States
212 332 3241
https://www.axsome.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 545

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Herriot Tabuteau M.D.	Founder, Chairman, CEO & President	1,32M	N/D	1968
Mr. Nick Pizzie CPA, M.B.A.	Chief Financial Officer	732,94k	N/D	1975
Mr. Mark L. Jacobson	COO & Secretary	784,66k	N/D	1983
Mr. Hunter Murdock Esq.	General Counsel & Secretary	735,39k	N/D	1980
Dr. Amanda Jones Pharm.D.	Senior Vice President of Clinical Development	N/D	N/D	1983
Ms. Lori Englebert M.B.A.	Executive Vice President of Commercial & Business Development	N/D	N/D	1978
Joseph Debrah-Afful CPA, M.B.A.	Director of Finance	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Governance aziendale

L'ISS Governance QualityScore di Axsome Therapeutics, Inc. al 1 aprile 2024 è 8. I criteri di valutazione fondamentali sono revisione: 8; Consiglio di Amministrazione: 8; diritti degli azionisti: 8; retribuzione: 8.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.